Patents by Inventor Ronnie C. Hanecak
Ronnie C. Hanecak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110124715Abstract: Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases are also provided.Type: ApplicationFiled: August 4, 2010Publication date: May 26, 2011Inventors: Ronnie C. Hanecak, Kevin P. Anderson, C. Frank Bennett, Ming-Yi Chiang, Vickie L. Brown-Driver, David J. Ecker, Timothy Vickers, Jacqueline R. Wyatt
-
Patent number: 7067497Abstract: Modified oligonucleotides having a GGG motif sequence and a sufficient number of flanking nucleotides to modulate the telomere length of a chromosome are provided. Methods of modulating telomere length of a mammalian chromosome in vitro and in vivo are also provided, as are methods for inhibiting the division of a malignant mammalian cell and for modulating the effects of cellular aging.Type: GrantFiled: January 2, 2002Date of Patent: June 27, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: Ronnie C. Hanecak, Kevin P. Anderson, C. Frank Bennett, Ming-Yi Chiang, Vickie L. Brown-Driver, David J. Ecker, Timothy A. Vickers, Jacqueline R. Wyatt
-
Patent number: 6995146Abstract: Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.Type: GrantFiled: May 11, 2001Date of Patent: February 7, 2006Assignee: Isis Pharmaceuticals, Inc.Inventors: Kevin P. Anderson, Ronnie C. Hanecak, Chikateru Nozaki, F. Andrew Dorr, T. Jesse Kwoh
-
Publication number: 20040049021Abstract: Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.Type: ApplicationFiled: June 4, 2003Publication date: March 11, 2004Inventors: Kevin P. Anderson, Ronnie C. Hanecak, Chikateru Nozaki, F. Andrew Dorr, T. Jesse Kwoh
-
Publication number: 20040033978Abstract: Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.Type: ApplicationFiled: June 9, 2003Publication date: February 19, 2004Inventors: Kevin P. Anderson, Ronnie C. Hanecak, Chikateru Nozaki, F. Andrew Dorr, T. Jesse Kwoh
-
Publication number: 20030171313Abstract: Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.Type: ApplicationFiled: May 11, 2001Publication date: September 11, 2003Inventors: Kevin P. Anderson, Ronnie C. Hanecak, Chikateru Nozaki, F. Andrew Dorr, T. Jesse Kwoh
-
Patent number: 6608191Abstract: Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.Type: GrantFiled: October 18, 2000Date of Patent: August 19, 2003Assignee: ISIS Pharmaceuticals, Inc.Inventors: Kevin P. Anderson, Ronnie C. Hanecak, Chikateru Nozaki
-
Publication number: 20030096776Abstract: Modified oligonucleotides having a GGG motif sequence and a sufficient number of flanking nucleotides to modulate the telomere length of a chromosome are provided. Methods of modulating telomere length of a mammalian chromosome in vitro and in vivo are also provided, as are methods for inhibiting the division of a malignant mammalian cell and for modulating the effects of cellular aging.Type: ApplicationFiled: January 2, 2002Publication date: May 22, 2003Applicant: ISIS Pharmaceuticals, Inc.Inventors: Ronnie C. Hanecak, Kevin P. Anderson, C. Frank Bennett, Ming-Yi Chiang, Vickie L. Brown-Driver, David J. Ecker, Timothy A. Vickers, Jacqueline R. Wyatt
-
Patent number: 6423489Abstract: Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.Type: GrantFiled: May 30, 1995Date of Patent: July 23, 2002Assignee: Isis Pharmaceuticals, Inc.Inventors: Kevin P. Anderson, Ronnie C. Hanecak, Kazuya Hoshiko, Chikateru Nozaki, Tsukasa Nishihara, Hiroshi Nakatake, Fukusaburo Hamada, Tatsuo Eto, Shinichi Furukawa, Shoji Furusako, Thomas W. Bruice, Walter F. Lima
-
Patent number: 6391542Abstract: Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.Type: GrantFiled: May 17, 1996Date of Patent: May 21, 2002Assignee: Isis Pharmaceuticals, Inc.Inventors: Kevin P. Anderson, Ronnie C. Hanecak, Kazuya Hoshiko, Chikateru Nozaki, Tsukasa Nishihara, Hiroshi Nakatake, Fukusaburo Hamada, Tatsuo Eto, Shinichi Furukawa, Shoji Furasako, Thomas W. Bruice, Walter F. Lima
-
Patent number: 6284458Abstract: Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.Type: GrantFiled: March 9, 1995Date of Patent: September 4, 2001Assignee: Isis Pharmaceuticals, Inc.Inventors: Kevin P. Anderson, Ronnie C. Hanecak, Kazuya Hoshiko, Chikateru Nozaki, Tsukasa Nishihara, Hiroshi Nakatake, Fukusaburo Hamada, Tatsuo Eto, Shinichi Furukawa
-
Patent number: 6174868Abstract: Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.Type: GrantFiled: December 10, 1997Date of Patent: January 16, 2001Assignee: Isis Pharmaceuticals, Inc.Inventors: Kevin P. Anderson, Ronnie C. Hanecak, Chikateru Nozaki
-
Patent number: 5952490Abstract: Modified oligonucleotides having a conserved G.sub.4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus such as HSV-1 or phospholipase A.sub.2 or to modulate the telomere length of a chromosome are provided. G.sub.4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnosis and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A.sub.2 are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to plat a role in the aging process of a cell and in control of malignant cell growth.Type: GrantFiled: June 12, 1995Date of Patent: September 14, 1999Assignee: Isis Pharmaceuticals, Inc.Inventors: Ronnie C. Hanecak, Kevin P. Anderson, C. Frank Bennett, Ming-Yi Chiang, Vickie L. Brown-Driver, David J. Ecker, Timothy A. Vickers, Jacqueline R. Wyatt, Jean Louis Imbach
-
Patent number: 5672472Abstract: Methods useful for the determination of oligomers which have specific activity for a target molecule from a pool of primarily randomly assembled subunits are provided. The disclosed methods involve repeated syntheses of increasingly simplified sets of oligomers coupled with selection procedures for determining oligomers having the highest activity. Freedom from the use of enzymes allows the application of these methods to any molecules which can be oligomerized in a controlled fashion.Type: GrantFiled: February 22, 1994Date of Patent: September 30, 1997Assignee: ISIS Pharmaceuticals, Inc.Inventors: David J. Ecker, Jacqueline Wyatt, Thomas W. Bruice, Kevin Anderson, Ronnie C. Hanecak, Timothy Vickers, Peter Davis
-
Patent number: 5514577Abstract: Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a herpesvirus gene corresponding to one of the open reading frames UL5, UL8, UL9, UL20, UL27, UL29, UL30, UL42, UL52 and IE175 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site, a coding region or a 5'-untranslated region. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide of the invention are disclosed.Type: GrantFiled: March 12, 1993Date of Patent: May 7, 1996Assignee: Isis Pharmaceuticals, Inc.Inventors: Kenneth G. Draper, Stanley T. Crooke, Christopher K. Mirabelli, David J. Ecker, Ronnie C. Hanecak, Kevin P. Anderson, Vickie L. Brown-Driver, Jacqueline R. Wyatt